Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline versus transdermal nicotine patch for smoking cessation
2004-001607-35Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of varenicline and nicotine in nicotine dependence (2 arms), sponsored by Pfizer. Primary endpoint: 4-week Continuous Quit Rate. Started Feb 2005; status: completed.
02
Drugs
vareniclinenicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2004-001607-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001607-35.